These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 32656741)
1. Role of the DEK oncogene in the development of squamous cell carcinoma. Ishida K; Nakashima T; Shibata T; Hara A; Tomita H Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741 [TBL] [Abstract][Full Text] [Related]
2. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization. Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425 [TBL] [Abstract][Full Text] [Related]
4. DEK::AFF2 Fusion-Associated Squamous Cell Carcinoma: A Case Series with Literature Review on an Emerging and Challenging Entity. Amin SE; Lewis JS; Bridge JA; Hang JF; Naik U; Bishop JA; Saluja K Head Neck Pathol; 2024 Sep; 18(1):86. PubMed ID: 39312022 [TBL] [Abstract][Full Text] [Related]
5. The DEK oncoprotein and its emerging roles in gene regulation. Sandén C; Gullberg U Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544 [TBL] [Abstract][Full Text] [Related]
6. Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093 [TBL] [Abstract][Full Text] [Related]
7. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808 [TBL] [Abstract][Full Text] [Related]
8. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology. Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636 [TBL] [Abstract][Full Text] [Related]
9. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival. Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316 [TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656 [TBL] [Abstract][Full Text] [Related]
11. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation. Adams AK; Hallenbeck GE; Casper KA; Patil YJ; Wilson KM; Kimple RJ; Lambert PF; Witte DP; Xiao W; Gillison ML; Wikenheiser-Brokamp KA; Wise-Draper TM; Wells SI Oncogene; 2015 Feb; 34(7):868-77. PubMed ID: 24608431 [TBL] [Abstract][Full Text] [Related]
12. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]. Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474 [No Abstract] [Full Text] [Related]
13. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922 [TBL] [Abstract][Full Text] [Related]
14. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392 [TBL] [Abstract][Full Text] [Related]
15. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress. Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463 [TBL] [Abstract][Full Text] [Related]
17. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis. Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610 [TBL] [Abstract][Full Text] [Related]
18. First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report. Savari O; Chang JC; Bishop JA; Sakthivel MK; Askin FB; Rekhtman N J Thorac Oncol; 2022 Aug; 17(8):1050-1053. PubMed ID: 35773081 [TBL] [Abstract][Full Text] [Related]
19. The Complexity of DEK Signaling in Cancer Progression. Teng Y; Lang L; Jauregui CE Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531 [TBL] [Abstract][Full Text] [Related]
20. The unique DEK oncoprotein in women's health: A potential novel biomarker. de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]